HK Stock Market Move | CF PHARMTECH (02652) rose nearly 8% in morning trading; core management voluntarily extended the lock-up period; the chairman recently increased his shareholding.

CF PHARMTECH (02652) rose nearly 8% in morning trading. As of press time, it was up 4.58% at HK$6.4, with a turnover of HK$18.2669 million. On the news front, the latest data from the Hong Kong Stock Exchange shows that on October 6, Chairman and Chief Executive Officer Liang Wenqing increased his shareholding in CF PHARMTECH by 19,300 shares at HK$6.9216 per share, for a total amount of approximately HK$133,600. After the increase, his latest shareholding stood at approximately 60.7165 million shares, representing an 18.74% stake. It is worth noting that Chairman, Executive Director and Chief Executive Officer Dr. Liang Wenqing and the company's co-founder, Executive Director and Chief Scientific Officer Dr. Li Li recently made a voluntary commitment to further extend the lock-up period on their shares by 6 months after the original lock-up period expires on October 7. The extended lock-up period runs from October 8, 2026 to April 7, 2027.